Investigational Therapy Denosumab Increased Bone Mineral Density With Twice-Yearly Dosing; One Year Data Published In NEJM

... Amgen (NASDAQ: AMGN), the world''s largest biotechnology company, announced today the publication of Phase 2 data demonstrating twice-yearly injections of denosumab (previously referred to as AMG 162), a RANK Ligand inhibitor, significantly increased bone mineral density (BMD) in the total hip, lumbar spine, distal 1/3 radius and total body compared to placebo... click link for more info. ...